• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Laser mammography firm targets Europe

Article

Imaging Diagnostic Systems could soon make the jump from a development-stage company to a full-fledged vendor of medical systems. The company has received regulatory approval to apply the CE Mark to its computed tomography laser mammography (CTLM) system

Imaging Diagnostic Systems could soon make the jump from a development-stage company to a full-fledged vendor of medical systems. The company has received regulatory approval to apply the CE Mark to its computed tomography laser mammography (CTLM) system and is now clear to begin marketing the product in countries in the European Union.

The CE mark is accepted in other parts of the world, the company noted, but not the U.S., where CTLM is awaiting FDA review as part of the premarket approval process. The application is expected to be complete early this year. Imaging Diagnostic Systems is seeking a PMA for the system to be used as an adjunct to conventional mammography and for clinical examination to aid in the detection of breast abnormalities.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.